Follow
About Nilus
Nilus Mattive bought his first stock in the sixth grade and has remained fascinated by the financial markets ever since. After graduating with a triple major in philosophy, theology, and English, he began his professional career at Jonathan Steinberg's Individual Investor Group. Mr. Mattive later edited Standard & Poor's flagship investment newsletter for five years and wrote The Standard & Poor's Guide for the New Investor, published by McGraw Hill. He has since built up an enviable 15-year track record of winning income at the helm of various newsletters and trading services, including Weiss Ratings' Income Superstars and Superstar Trader. He now serves as editor of Weiss Ratings' Safe Money Report.
Nilus's Articles
My daughter and I have been in Portugal for the last several days. She came here to compete in an international surf contest. I came to watch, eat a metric ton of seafood, and get a general sense of what’s happening in Europe economically and otherwise. One suggestion: Consider the Franklin International Core Dividend Tilt Index ETF (DIVI), says Nilus Mattive, editor of Safe Money Report.
Nilus Mattive
INCOME
Tickers: DIVI
The average American federal income tax bill was $13,890 in 2022, the latest year for which we have that level of data. It takes about two American taxpayers to “fly” a single F-18 for one hour. Yet this is still just a tiny slice of US military spending. That’s one reason I’ve been recommending General Dynamics Corp. (GD), advises Nilus Mattive, editor of Safe Money Report.
Nilus Mattive
INDUSTRIALS
Tickers: GD
I don’t base my investment recommendations on charts. Nor do I consider myself an expert on technical analysis. But as the expression reminds us, some pictures are worth 1,000 words. And three charts form my basis for believing the stock market is heading for a major drop, advises Nilus Mattive, editor of Safe Money Report.
Nilus Mattive
STOCKS
Tickers: SPX
If you know anything about me, you know I’m concerned about the AI boom. However, there is one big, obvious, already-starting-to-happen benefit from AI, too. I’m talking about AI’s ability to help develop novel drugs and disease treatments at lightning speed. You can play the trend with the iShares US Pharmaceuticals ETF (IHE), writes Nilus Mattive, editor of Safe Money Report.
Nilus Mattive
HEALTHCARE
Tickers: IHE